Superworth

Repligen price to free cash flow RGEN

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
89.2×
10-year median
121×
Against its 10-year history
31st
percentile: 0 is its lowest day, 100 its highest
10-year range
42.0× to 424×
Peer median
21.8×

Repligen's price to free cash flow is 89.2× as of Oct 23, 2026.

That is below its ten-year median of 121×, lower than on 69% of days in the last ten years.

Over that time it ranged from 42.0× in Apr 2025 to 424× in Oct 2021.

The median for 10 biotech stocks of a similar size is 21.8×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far89.2×54.7×95.6×
202585.1×42.0×87.5×
202460.8×57.0×142×
202399.2×66.8×171×
2022148×143×308×
2021386×223×424×
2020213×91.5×229×
2019115×69.5×146×
201870.2×66.9×187×
2017189×176×390×
2016213×60.5×235×
2015106×32.6×170×
201432.8×18.4×43.1×
201318.7×15.3×23.1×
201218.9×17.0×64.6×

Against its peers

Companies in Biotechnology nearest Repligen's size, closest first, today.

CompanyPrice to free cash flow
RGENRepligen89.2×
KRYSKrystal Biotech35.8×
TECHBIO-TECHNE43.2×
HALOHalozyme Therapeutics17.7×
NBIXNeurocrine Biosciences16.7×
EXELExelixis13.6×
INCYIncyte12.2×
UTHRUnited Therapeutics23.1×
ALNYAlnylam Pharmaceuticals37.8×
ADMAAdma Biologics20.5×
ONCBeOne Medicines32.3×
Peer median21.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Repligen

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.